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ABSTRACT 
THE PINEAL GLAND, VIA MELATONIN, PROTECTS DNA, COORDfNATES THE 
ENDOCRINE SYSTEM WITH THE IMMUNE SYSTEM AND CONTROLS THE 
TIMING OF REPRODUCTION 
By Craig Lincoln Anthony, M.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2001 
Director: Dr. Hugo Seibel 
The pineal gland secretes the hormone melatonin (n-acetyl-5-methoxytryptamine) 
with a circadian rhythm. This secretion's rhythm becomes disrupted with age. When 
melatonin secretion is decreased with advanced age, the immune, endocrine and 
reproductive systems fail to function optimally. Melatonin possesses lipophilic and 
anti-oxidant properties, providing it with access to nuclei. Melatonin protects the DNA, 
preventing cancerous mutation. Hippocampal degeneration and age increase and prolong 
the adrenocortical responses to stress. Melatonin supplementation reduces the prolonged 
exposure to harmful hormones. 
INTRODUCTION 
All organisms function according to a biological rhythm, usually circadian, from 
the subcellular level through the organismal level (130). These rhythms generally become 
increasingly disrupted with age. Recently, scientific debate has speculated that these 
disruptions of rhythm may be the result of ageing. They could also be a significant 
contributor to ageing. With the discovery of melatonin as the hormone directly related to 
these rhythms, the query whether these disturbances are causing ageing or are the result of 
ageing has received increasing interest. This study is less concerned with preventing 
ageing and more interested in melatonin's ability to maintain a more youthful homeostasis 
with increasing age through supplementation, possibly via maintaining hormone and 
system balance, possibly via maintaining youthful hormonal concentrations and 
homeostasis. Indirectly, this supplementation may affect the longevity of an organism by 
retaining the environmental plasticity seen in youth. 
The pineal gland secretes the hormone melatonin (n-acetyl-5-methoxytryptarnine). 
Melatonin is secreted with a circadian rhythm and a plasma concentration peak 3 to I 0 
times higher than base levels at approximately 3 a.m. Melatonin, produced and secreted 
without significant storage, is the chemical signal relaying circadian rhythms to almost 
every cell in the body. Melatonin's lipophilicity provides it broad access to cellular 
cytoplasm, nuclei and multiple membrane receptor locations. Melatonin is produced in the 
pineal gland from n-acetylserotonin. N-acetylserotonin is converted from serotonin by 
n-acetyltransferase, the rate limiting enzyme, and converted into melatonin by 
hydroxyindole-o-methyltransferase (HIOMT). The two step degradation consists of a 
6-hydroxylation by microsomal monoxygenases followed by conjugation from a cytosolic 
sulfotransferase. This produces 6-sulfatoxymelatonin (aMT6), the main metabolite, in 
70-80% of degraded melatonin (124). Minor quantities of melatonin (10-20%) are 
conjugated to glucuronic acid [Fig. 1]. The hydroxylation that occurs in the liver is 
inducible by phenobarbital and polyaromatic hydrocarbons (124). This secretion is 
consistent regardless of species and diurnal or nocturnal activity. Thus, melatonin is 
recognized as an internal synchronizer of cosmic chronology. 
2 
The pineal gland, epiphysis cerebri, is a small cone-shaped structure suspended 
from the caudal epithalamus superior and caudal to the midbrain. The pineal gland 
contains three main cell types; calcareous granules, astrocyte resembling glial cells and 
parenchymal cells. The parenchymal cells extend into the basal lamina of the perivascular 
space (82). The pineal gland is well vascularized with fenestrated capillaries and receives 
only one innervation. These postganglionic sympathetic nerves arrive at the pineal gland 
from the superior cervical ganglia. This is the fnal step of a complicated pathway that 
conveys environmental photoperiod information from the retina to the pineal gland. This 
retinal photostimulation is relayed to the supra-chiasmatic nucleus (SCN). From the 
hypothalamus, the nerve signal is then sent to the upper thoracic intermediolateral cell 
columns. Preganglionic sympathetic neurons exit through the white rarni, reach the 
sympathetic trunks and finally the superior cervical ganglia. The final step in the regulatory 
pathway of melatonin is the neurotransmitters released from noradrenergic terminals that 
originate in the superior cervical ganglia (80), targeting the pineal gland. This complicated 
pathway of innervation may be the result of a long evolutionary history of the mammalian 
pineal gland. 
Another regulatory pathway of melatonin is not directly linked to light/dark 
modulations. Tachykinins may regulate pineal function, independent from environmental 
light (19). Substance P (SP) and neurokinin A (NKA) are either released from nerve fibers 
not originating in the superior cervical ganglia (SCG) or are produced in the pineal gland. 
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The exact origin is not known conclusively, although it is speculated that they are 
produced in the pineal gland. Removing the SCN did not result in a change in 
concentration of SP in the pineal gland (111 ). Research looking for the gene and mRNA 
encoding the synthesis of preprotachkinin peptides in the nucleus of pineal gland cells is 
currently being explored to defnitively prove that tachykinins are produced in the pineal 
gland. Neuropeptide K and neuropeptide gama are also suspected to be present, as both 
are co-synthesized with SP within preprotachykinin peptides. HPLC experiments revealed 
an inconclusive, immunoreactive peak of similar weight to neuropeptide K ( 19). 
Unlike melatonin and the noradrenergic neurotransmitters, NKA did not change 
concentration in the pineal gland with environmental light ( 19). Pineal NKA 
concentrations were no different in rats killed during light or dark periods. Tachykinins do 
not express circadian rhythms, although they are sensitive to endocrine regulation. 
Gonadotropins and gonadal steroids modulate the concentrations of tachykinins in the 
pineal gland, while melatonin has no direct affect (19). Pineal tachykinins increased in 
concentration following castration. The castrated animals' pineal NKA concentrations 
returned to normal with testosterone replacement therapy (19). Testosterone has an 
inhibitory effect on pineal tachykinin production (19). Superior cervical ganglionectomy 
also resulted in an increase in pineal tachykinin concentrations. Although pineal 
tachykinins are not released by the noradrenergic nerve terminals originating in the SCN, 
the neurotransmitters that are released by these terminals inhibit pineal tachykinin 
production. 
The manner of regulation the tachykinins exert on the pineal gland is unknown. SP 
receptors have been found in the pineal gland. SP has been found to increase adenylate 
cyclase activity in the pineal gland, and the other tachykinins have shown stronger affects 
than SP in the salivary gland (123). Tachykinins may be transported to the pineal gland or 
synthesized in situ. They are regulated by androgen concentrations and noradrenergic 
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nerves originating in the SCN. Although both of these forms of regulation follow circadian 
rhythms, tachykinin concentrations in the pineal gland do not 
Tachykinin, NKA., concentrations in the hypothalamus (39) and anterior pituitary 
(22) increase when exposed to testosterone and decrease with the loss of testosterone. 
This is the opposite effect seen in the pineal gland. The tachykinins role in the complicated 
regulation of melatonin production is worthy of more research. Tachykinins possess the 
unique quality, with regard to melatonin regulation, of being independent of circadian 
rhythm. Estradiol and progesterone affect melatonin secretion. Norepinephrine synthesis is 
modifed by gonadal hormones in the sympathetic nerves originating in the SCN and 
terminating at the pineal gland (I 06). Therefore, it is logical that gonadal hormones affect 
tachykinins to some extent, and tachykinins help modulate melatonin regulation with 
contributions to this indirect relationship with circadian rhythms. 
One of the crucial elements for the evolution of life, the sun, displays rhythms of 
about 24-hour duration. These are circadian rhythms. Due to the importance of this 
rhythm, melatonin has been conserved from species to species. 
At its most basic level, evolution is the plasticity a species expresses as a result of 
changes in its environment making the organism more successful. The earth's revolution 
around the sun is the largest and most consistent influence on the earth's environment. It 
contributes to almost every organisms' development on the planet. Therefore, it is not 
unexpected that not only has melatonin developed at an early stage of evolution, but it has 
remained unchanged throughout this development. Organisms have evolved multiple uses 
for this constant in their biology. 
If melatonin proves to be one of the earliest free radical scavengers, this would 
almost certainly defne the evolutionary origin of melatonin. Melatonin's protection 
against free radical damage could have led to other uses in organisms due to its 
photoperiodic responses and photooxidation with light ( 46). Melatonin functioned as a 
dark mediator, even at the unicellular organism level. Melatonin conveyed photoperiodic 
and temperature information to the unicellular organism Gonyaulax (46). In Gonyaulax, 
melatonin levels are highest in dark and low temperature environments ( 15 degrees C) 
(46). More evolved organisms retained these functions of melatonin while finding 
additional uses for the molecule. Melatonin remains a valuable free radical scavenger in 
areas exposed to high levels of hydroxyl radicals and structures requiring additional 
protection, e.g., CNS and DNA 
Humans, one of the most evolutionarily advanced species on the planet, have 
developed many uses for the consistency of melatonin secretion. Melatonin is found 
throughout the body and has access everywhere. Melatonin is mainly produced in the 
pineal gland, but also in the retina and GI tract. Two other consistencies in human 
melatonin production are the calcification of the pineal gland with age and the steady 
decline of melatonin production with age after reproductive viability has expired. 
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The calcification of the pineal gland is not related to production of melatonin as it 
does not change the histology of the pinealocyte (132) or HIOMT activity, the enzyme 
responsible for facilitating melatonin production (137). Increased excretion of melatonin 
with age is also unlikely to be the cause of lowered plasma concentrations as urinary 
6-hydroxymelatonin, melatonin's main metabolite, is reduced proportionally (71). 
The sympathetic innervation of the pineal gland may be the cause of decreased 
melatonin production with age. Pinealocytes have B-adrenergic, membrane bound 
receptors that respond to norepinephrine by stimulating melatonin synthesis. Studies in 
rodents have shown both a decrease in B-adrenergic receptors and receptor sensitivity 
with age (41). This is, currently, the most probable explanation for decreased melatonin 
synthesis and plasma concentrations in aged humans. 
Decrease in melatonin synthesis may also be due to altered physiology in the brain 
causing a disruption in yearly circadian rhythm, rather than daily circadian rhythm. As 
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melatonin is produced at night, melatonin production increases during winter months with 
the shortest photoperiod. Other studies have shown peak melatonin production to exist in 
both summer and winter with lowest levels in spring and fall (7). In some young, healthy 
male individuals, melatonin production is highest in the summer months (130). Other 
studies have found no seasonal variations in melatonin plasma concentrations or no 
seasonal variations in concentration, but a phase advance of about ninety minutes during 
winter months (53). These variations in results suggest a complicated process of 
converting photoperiod to melatonin production. A consistency in study results is the 
summer months peak of melatonin in healthy, young males. The variations suggest further 
brain activity, regulating melatonin synthesis. This processing may occur in the SCN 
before a sympathetic nerve signal is sent to the pineal for melatonin synthesis. Additional 
research is necessary to determine if the alterations in seasonal melatonin production are 
correlated to reproductive success, different individuals hormonal balance or simply 
latitude. 
Aged patients show a decrease in melatonin production with a minimum plasma 
concentration in October (130). Alzheimer patients' melatonin production is further 
depressed, also with a minimum concentration in October. In both cases, the decrease in 
melatonin secretion is accompanied by an alteration of the seasonal variability of melatonin 
secretion. The phase shift in seasonal variability of secretion would more likely result from 
alterations or diminished brain processing of photo period signals than decreased number 
or sensitivity of B-adrenergic receptors. 
With the complexity of photoperiod information processing and delivery to the 
pineal gland, it is unlikely the disturbance in rhythm seen with age is isolated to one area of 
the brain. The SCN would be the first area to investigate. Telencephalon and cerebrum, 
areas involved in Alzheimer's disease, could also be involved, due to the correlation 
between extremely low melatonin secretion and the disease. Diencephalon structures 
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associated with sensory information or homeostasis, thalamus, hypothalamus, may also be 
involved, due to their common embryonic development and interaction with the 
epithalamus, pineal gland. 
As melatonin's regulator in the human brain, the supra-chiasmatic nucleus has been 
dubbed the internal pacemaker. Retinal signals are transmitted to the SCN. These retinal 
signals are a result of environmental photoperiods. The SCN transmits neural inputs to the 
pineal gland. The pineal gland responds by producing and secreting melatonin in a 
circadian fashion. The timing and expression of seasonal and daily light regulate circadian 
rhythms crucial to every system in the body, most notably reproduction and the 
equilibrium present between the endocrine and immune systems. Melatonin is a lipophilic 
molecule, allowing it access to almost every cell in the body. Circadian regulation of the 
reproductive system is crucial for seasonal breeders. Melatonin receptors are more 
prevalent and express a lower affinity in birds than mammals (16). This may allow for 
more precise regulation from melatonin. Birds produce melatonin as a result of light 
illumination through their skull, as well as retinal signaling. Birds may have evolved with 
additional uses for melatonin. They may use melatonin for migrational navigation and 
timing. 
In humans, melatonin increases in production and secretion nocturnally, with a 
peak concentration between two and three a.m. As an organism ages, a peak of melatonin 
production is seen prior to puberty and gradually declines until death. The initial decline in 
melatonin plasma concentration is due to the expansion of the vascular system with 
increased organism size. This decline initiates puberty through melatonin's decreased 
inhibition of the endocrine system, specifically gonadotropins and androgens. The gradual 
decline in melatonin production with age is not caused by the calcification of the pineal 
gland. Melatonin production decreases as a result ofreduced adrenergic innervation of the 
pineal gland and a decrease in the concentration of B-adrenergic receptors on the 
membranes of pinealocytes (108). Melatonin is primarily produced in the pineal gland 
under the influence of the SCN, although melatonin is also produced in retinal cells and 
enterochromaffin cells from the GI tract to a lesser extent. 
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Circadian rhythms have been known to influence the ageing of species for decades. 
In 1972, Pittendrigh and Minis shortened the life span of Drosophila me/anogaster by 
transplanting flies raised on a 24 hour cycle to either a 21 hour or 27 hour cycle ( 117). 
These rhythms are primarily controlled by the SCN in humans. The SCN does not exhibit 
morphological changes with age, but rather changes in its function (105). Body 
temperature is regulated by the SCN. Body temperature has a strong influence on sleep­
wake cycles. Sleep disturbances are among the chief medical complaints in older patients 
(105). 
A FREE RADICAL SCA VEN GER 
Melatonin is intimately involved in the regulation of the immune and reproductive 
systems. It fights cancer, facilitates pregnancy and creates a hormonal homeostasis. Yet, 
melatonin's evolutionary value may result from one necessity for survival of every 
organism, protecting the DNA from free radical damage. 
Melatonin's original development as a free radical scavenger could be solidified if a 
correlation was found between melatonin' s phylogenic age and the development of aerobic 
respiration. Aerobic respiration consumes nearly all cellular oxygen. The 1-2% of oxygen 
that is not completely reduced may form either a superoxide anion radical or hydrogen 
peroxide (126). Neither molecule is as cytotoxic as hydroxide radicals, but hydrogen 
peroxide can rapidly be converted into the hydroxide radical in the presence of 
redox-active transition metals through the Fenton reaction. Melatonin's effectiveness as a 
free radical scavenger with a specific affinity to hydroxide radicals was compared to 
mannitol and glutathione, two strong free radical scavengers (125). This experiment 
discovered that melatonin was as effective a scavenger of hydroxide radicals as glutathione 
and mannitol at one sixth and one tenth the concentration, respectively. 
Melatonin has been found in almost every species in the animal kingdom. 
Melatonin was originally thought to be exclusively produced by the pineal gland. With the 
discovery of melatonin production in unicellular organisms, e.g., the dinofagellate 
Gonyaulax polyedra, it was realized that melatonin is also produced by other cells than 
pinealocytes. 
If melatonin is found to be an early free radical scavenger, this would explain 
melatonin's affinity, bordering on specificity, to hydroxide radicals, the most destructive 
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free radicals. Melatonin's high lipophilicity is additional evidence supporting melatonin's 
original development as a free radical scavenger. The first free radical scavenger would 
certainly evolve to protect organisms' DNA. Melatonin is the most well designed free 
radical scavenger for this task. 
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An experiment using safrole, a carcinogen found in sassagras oil, supported claims 
ofmelatonin's role in DNA protection (126). Safrole induces oxidative radical attack of 
DNA, thus promoting cancer. A low dose of melatonin (.2 mg/kg) was administered to 
rats prior to a safrole treatment. This pretreatment reduced safrole's damage of hepatic 
DNA by over 40%. With a higher dosage pre-treatment (.4 mg/kg), melatonin reduced 
safrole's damage of DNA to within 1% of the control. 
As these results are more significant regarding the prevention of cancer, rather 
than the treatment, another experiment was designed to determine melatonin's protection 
of DNA at physiological concentrations (126). Safrole was injected into rats during the 
day (low plasma concentrations of melatonin) and at night (peak plasma concentrations of 
melatonin) Safrole damage to DNA was reduced by over 20% when injected at night, 
when compared to day injections. 
Melatonin may have evolved for the protection of DNA from free radical damage, 
although other forms of protection have been attributed to this hormone. Oxygen-centered 
radicals can suppress the calcium pump in cardiomyoctes. Melatonin protects rat cardiac 
sarcolemmas from these free radicals (126). Melatonin's peripheral protection against free 
radicals would have evolved after its ability to protect nuclear DNA, or would have been a 
coincidence of similar molecular design requirements. In either case, other free radical 
scavengers would later evolve to help protect a wider assortment of biomolecules 
throughout the organism. 
Reiter proposed the mutual evolution of aerobic respiration and melatonin for 
protection against the free radicals aerobic respiration produces (126). He used the 
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physicochemical properties of melatonin to support the use of membrane-bound receptors 
for melatonin. These receptors are required for the more evolutionarily advanced functions 
of melatonin, including circadian rhythm regulation, hormonal balance, coordination of 
immune and reproductive systems and possibly the regulation of metabolism in hibernating 
organisms. 
The addition of membrane receptors reflects organisms' evolution to increase the 
uses of melatonin. Melatonin has not changed in chemical structure throughout 
evolutionary time (126). The dinoflagellate, Gonyaulax po/yedra, not only produces 
melatonin, but it cycles with a circadian rhythm, as seen in humans ( 107). The membrane 
receptors increase the potential effects of melatonin, but are yet to be widely distributed 
( 126). 
The actions of melatonin through receptors, combined with melatonin's 
lipophilicity, give this molecule the diversity to affect almost every cell in the body. 
Melatonin can transverse the blood brain barrier (47), or travel in CSF. Melatonin is 
non-toxic at high plasma concentrations. Reiter was unable to produce toxic side effects 
or prooxidant activity with high melatonin doses chronically administered (126). Being 
non-toxic at high concentrations, melatonin can greatly vary its physiological plasma 
concentrations with circadian rhythm, and it can easily be used as a clinical treatment or as 
preventive medication. Melatonin can readily be enzymatically degraded in the liver with 
retinal exposure to light acting as an initiator. 
Melatonin's main target is the nucleus. Its protection of DNA from free radical 
damage is valuable, but this nuclear access has other benefits. Melatonin may be bound in 
the nucleus and could directly affect gene transcription (78). Dr. Reiter has shown that 
melatonin intercalates with DNA (126). Melatonin is found in higher concentrations in the 
nucleus than the cytosol (78). This puts melatonin in a more direct position to infuence an 
organism and allow the organism to evolve tailored uses for such an ubiquitous molecule. 
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Melatonin is produced in a variety of tissues throughout the human body. Most 
tissues that produce melatonin also contain porphyrins producing high levels of free 
radicals (126). Circadian rhythmic melatonin production occurs in phylogenetically old, 
single celled organisms (107). The pineal gland does not appear crucial to the prevention 
of free radical damage or circadian rhythm in all species. Humans may have evolved a 
pineal gland as our systems became more complex. The pineal gland, devoted exclusively 
to melatonin production, may allow a more precise production and feedback of melatonin. 
This refinement of the use of melatonin may have allowed for another use. Melatonin may 
be the protector of DNA, allowing humans to reach reproductive maturity and increase the 
statistical chance of reproduction in such a complicated organism. The pineal gland begins 
to calcify and melatonin production diminishes as reproductive potential decreases. Free 
radical damage, DNA damage, disease and cancer rates increase. 
Rat lung and spleen tissue have been protected from oxidative damage to DNA by 
melatonin. In this respect, melatonin acts as an anti-oxidant, possibly scavenging free 
radicals. It is particularly well suited for protecting nuclear DNA due to its small size and 
lipophilicity. 
Reiter infected rats with the potential carcinogen, delta-Arninolevulinic acid 
(ALA)() 06). These rats showed higher levels of nuclear DNA and membrane oxidation in 
lung and spleen tissue than the controls. When melatonin was injected following the ALA 
injection, the test group's oxidation levels were similar to the control group's levels. 
Melatonin protects DNA and lipid membranes from oxidation by detoxifying OH and NO, 
scavenging H202 and stimulating other anti-oxidative enzyme activity() 06). 
Specifically, melatonin does not trap free radicals. It inhibits metal ion-catalyzed 
oxidation of these free radicals. Melatonin is precluded from the group of antioxidants that 
trap free radicals because it is a simple, substituted indole structure(lOO) This type of 
structure does not contain a removable hydrogen which is necessary and available in the 
phenoxyl position of alpha-tocopherol and other antioxidants. 
Melatonin acts as a preventive antioxidant by forming a bond between its ring 
nitrogen and the metal ion. This inhibits the catalyzation of oxidation. This type of 
antioxidant is not a scavenger, it is a preventive antioxidant. This antioxidant exhibits 
wider influences on the control of free radicals in the body than a scavenger, such as 
vitamin E. 
Other, in vitro, studies have shown melatonin to exhibit twice the free radical 
13 
protection than vitamin E(87) These authors readily admit that they do not have 
reproducible data supporting such results in vivo, but the in vitro experimental results are 
. . 
1mpress1ve. 
Melatonin undoubtedly shows multiple antioxidant properties, but these actions are 
not its primary function. Melatonin is a genetically, highly conserved molecule. Its main 
role, as an antioxidant, is to protect DNA 
OH free radicals are a primary destroyer of DNA Due to their structure, most free 
radical scavengers are not capable of crossing the cytosol and entering the nucleus of a 
cell. Even if free radical scavengers could exist in close proximity to DNA, the typical 
hydroxyl radical inflicts its damage on the genetic material before it migrates one or two 
of its molecular diameters(! 06). This leaves insufficient time to scavenge all these free 
radicals considering the dire consequences if one comes in contact with the DNA One 
reason melatonin may be highly conserved, genetically, could be to protect DNA from free 
radicals by inhibiting their formation. Melatonin's structure allows access to the nucleus 
and therefore the DNA, and its mechanism of preventing free radical damage is 
preemptive rather than reactive. These are traits valuable to the protection of DNA 
Melatonin may have evolved initially to protect DNA from free radical damage. It 
could then have developed into a more general antioxidant. As organisms became more 
complex, melatonin receptors allowed more diverse actions. Humans have developed 
multiple complex uses for melatonin. One of the most complex actions of this tropic 
hormone is maintaining the appropriate balances of almost every other hormone in the 
endocrine system. 
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ENDOCRINE SYSTEM AND REPRODUCTION 
The pineal-hypothalamic-pituitary axis is complex and its deterioration with age is 
not completely understood. Biochemical and physiological responses to hormones 
decrease with age. Most steroid receptors do not lose affinity for their hormones, but 
reduce in concentration with age. B-adrenergic receptors form an activated complex with 
adenylate cyclase. This complex, specifically, exhibits a decline in affinity for 
norepinephrine with age (127). During the night, there is an increase in adrenergic input to 
the pineal gland through the sympathetic nervous system (127). The concentration of 
B-adrenergic receptors increases on the pineal gland with light exposure (127). As the 
pineal gland ages, it is unable to accommodate these necessary changes in receptor density 
and sensitivity to support normal melatonin secretions. Norepinephrine has less affect on 
the pineal gland in aged individuals. Melatonin secretion is decreased at night, as it is 
mediated by norepinephrine through the B-adrenergic receptors. The calcifications 
occurring in pineal glands with age are structural changes and do not appear to be the 
cause of decreased nocturnal melatonin secretion with age (35). 
Melatonin, TSH, prolactin and GH amplitudes are depleted with age (13). LH and 
FSH levels are elevated. Testosterone secretion is decreased. Cortisol loses some rhythm, 
but is changed little with age. 
LH concentrations begin to rise in older men as the testosterone levels begin to 
decrease. Without adequate levels of testosterone inhibition, LH levels are elevated. 
Aldosterone and prolactin are secreted rhythmically, with a peak at night. Both exhibit a 
decrease in this circadian amplitude with age. 
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A decrease in gonadal activity with age results in a compensatory rise in 
gonadotropin secretion. As the high concentrations of plasma LH are compatible with its 
circannual rhythm, the rhythmic hormonal secretion of the pituitary gland is independent 
of decreased gonadal hormone secretion and concentration in aged individuals ( 131 ). The 
rhythmic pituitary secretion is not degraded by the loss of gonadal hormones. This is true 
of both testosterone, which decreases with age, and estradiol and progesterone, which 
decrease after menopause. 
The pineal gland is intimately coordinated with the activities of the hypothalamus, 
median eminence and pituitary gland. Thus, it is not surprising that melatonin helps 
regulate release of gonadotropins (LH and FSH), prolactin and GH 
The pituitary stores and secretes gonadotropins and prolactin. The in vivo addition 
of melatonin has no affect on LH or prolactin storage in the pituitary (2). Melatonin 
produces an inhibitory influence on high levels of prolactin and gonadotropin secretion in 
the young(l 10). Thus, the highest concentrations of melatonin exist before puberty. The 
drop in melatonin promotes puberty by increasing gonadotropin secretion. Melatonin's 
affect on secretion and not storage suggest different regulatory mechanisms for each and 
the lack of influence melatonin exhibits on the biosynthetic pathway.(3) Pituitary tissue 
stores LH for future surges, such as inducing ovulation or puberty. Melatonin has been 
analyzed as a potential treatment to delay reproductive senescence.(76) This line of 
research logically followed the discovery ofmelatonin's ability to delay puberty by 
inhibiting prolactin and gonadotropin secretory surges.(30) The functional capacities, 
secretion of hormones, of the pituitary gland and the median eminence can be maintained 
and extended through reproductive senescence with melatonin supplements. When the 
anterior pituitary was transplanted from acyclic, senescent rats to cyclic, young rats with 
the cyclic rats anterior pituitary removed, the cyclic rats pituitary could not maintain 
normal estrous cycles.(110) There was a decrease in GnRH receptor numbers. This 
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decrease in receptor concentration is hypothesized to be the reason acyclic anterior 
pituitary glands can not maintain normal estrous cycles in cyclic rats. In youth, melatonin 
inhibits the pituitary's response to GnRH.(122) Contrarily, melatonin supplements, in aged 
females, increase GnRH mRNA production by 18%, returning GnRH levels to those of 
youth.(64) However, the functional status of the hypothalamic-pituitary system in 
senescence is still not well understood and is in need of further research to solidify existing 
theories. 
Although some of the mechanisms are not understood, many hormonal reactions to 
melatonin supplements are documented. When melatonin concentration is increased in 
young, cyclic rats, with high levels of gonadotropins, the gonadotropin secretion is 
decreased to lower levels.(3) The pituitary LH concentrations did not change and, 
although acyclic mammals secrete more gonadotropins than cyclic mammals, the pituitary 
tissue content remains constant. This could be a result of different, age dependent, 
selective factors regulating gonadotropin release from the pituitary gland;(3) different 
neuroendocrine mechanisms controlling the storage of gonadotropins in the pituitary 
tissue;(85) or alterations of hypothalamic-pituitary axis function relative to age(52). 
Regardless of the mechanism, melatonin's inhibitory affects are exerted on the secretory 
process rather than pituitary storage. 
The median eminence secretes prolactin and gonadatropins, primarily FSH. As in 
the pituitary, melatonin decreases prolactin and gonadotrophic release, in cyclic mammals, 
from the median eminence.(3) Similar to the pituitary, the median eminence tissue content 
ofLH changes little with age, although FSH content in the tissue of the median eminence 
decreases with age. FSH and LH secretions from the median eminence increase as the 
mammal becomes acyclic. The relative gonadotropin secretion from the median eminence 
is minor compared with the secretion from the anterior pituitary. 
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Melatonin does not change the tissue content of LH from the median eminence, 
nor the pituitary in cyclic or acyclic mamrnals(3). Melatonin decreases the pituitary LH 
secretion in cyclic animals. Melatonin does not change the LH secretion from the median 
eminence in cyclic mammals, as there is not significant LH secretion from the median 
eminence. 
The median eminence is more signifcant with regard to FSH, compared with other 
median eminence hormones. FSH is secreted and stored in similar concentrations in both 
the pituitary gland and the median eminence. Ageing increases both tissue storage and 
secretion of FSH, in the pituitary gland and median eminence. When melatonin is 
administered to cyclic mammals, median eminence and pituitary FSH secretion and tissue 
storage concentrations are lowered. Acyclic mammals respond to melatonin by decreasing 
FSH storage and secretion(3). Although the median eminence has much larger 
concentrations ofFSH than LH, the pituitary gland is primarily responsible for 
gonadotropin storage and secretion. Inhibin, a hormone produced by granulosa cells in 
atral follicles, declines in concentration as follicle cells are lost with age and menopause. 
Inhibin inhibits FSH secretion from the pituitary. With the loss of this inhibition, FSH 
plasma concentrations rise with age. 
Melatonin secretion varies with seasons, as well as day or night. Although the 
results vary based on )attitude, generally, the highest basal melatonin concentrations occur 
in February, and the lowest concentrations occur in Novermber(9). This corresponds with 
the shortest and longest sunlight exposure per day. February is two months after the 
winter solstice, and November is five months after the summer solstice. Research is 
needed to determine why the body produces minimum and maximum melatonin levels with 
this lag. Perhaps a correlation could be found between this seasonal lag, the daily lag (peak 
melatonin concentrations occur eight hours after sunset) and new neuronal growth, 
sensitivity or activity. 
19 
The SCN contains neurons controlling antidiuretic hormone (ADH) release. ADH 
concentrations also occur with seasonal variations (9). The highest concentrations occur in 
the fall and the lowest concentrations occur in the spring. This is opposite in cycle to 
melatonin. 
The SCN volume and ADH neuron concentrations are at a peak in fall and are 
lowest in summer (51 ). This reflects the seasonal variation in basal ADH concentrations. 
High concentrations of ADH inhibit the release of melatonin (118). Pinealectomy (a 
reduction in circulating melatonin concentrations) results in an increase in ADH 
concentrations. The feedback loop between melatonin and ADH may occur in the SCN, 
where ADH neurons and neuronal signals destined for the pineal gland are both processed 
with regard to retinal photoperiod input. ADH levels increase with age (9), as melatonin 
levels decrease along with a possible inhibition of ADH. 
Growth hormone basal levels peak at puberty and then continuously decline with 
advanced age. This decrease in GH is due to a decrease in production and pituitary 
responsiveness to GB-releasing factor(l 32). Decreases in plasma GH cause a decrease in 
protein synthesis, reduction in kidney and liver function, as well as a loss of bone and 
immune system deterioration(l 12). 
Growth hormone's response to GR-releasing hormone decreases with advanced 
age, as does prolactin's response to doperidone. Both GH and PRL secretions occur based 
on the 24 hour circadian cycle, depending on the sleep-wake cycle. GH and PRL are 
secreted in sleep, mirroring melatonin. GH gradually decreases in concentration with age, 
and prolactin's circadian periodicity is flattened out, losing its nocturnal peak. Melatonin 
supplements restore the peak secretion of prolactin at night, while dopamine decreases its 
secretion( 17). Low levels of prolactin make the immune system less productive. 
Growth hormone secretion mirrors the cyclic secretion seen in melatonin, with a 
nocturnal peak. A decrease in GH concentrations is seen in aged individuals. Although the 
cyclic pattern of release is not compromised, the amplitude is decreased(l 24). GH 
normalization is an important goal for many aged individuals, as it may reduce the 
increased occurrence of sleep disturbances seen in the aged.(56) 
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Prolactin is secreted with a circadian rhythm in humans, usually with a nocturnal 
peak. Prolactin peak concentrations also occur during daytime sleep ( 131 ). This dual 
control of prolactin secretion, sleep and circadian rhythm results in jet lag symptoms seen 
in travelers of multiple time zones (29). The intrinsic circadian rhythm of prolactin 
secretion is not in sync with sleep. Melatonin supplementation at high concentrations can 
reset these intrinsic circadian rhythms of prolactin secretion to correspond with 
appropriate sleep hours. Inconsistent results show both increases and decreases in 
prolactin amplitudes in response to melatonin supplements in elderly individuals (129). 
The circannual rhythm of prolactin secretion appears to remain consistent with age, 
although this is usually reported predominantly in women. Consistent circannual rhythms 
of prolactin are difficult to detect in men. 
Prolactin is mainly secreted and stored in the pituitary gland, as little prolactin is 
stored or secreted in the median eminence. Advanced age has no affect on prolactin 
storage in the pituitary, nor median eminence secretion. Age increases median eminence 
prolactin storage and decreases pituitary secretion. Melatonin supplements have no 
significant affect on cyclic nor acyclic mammals' pituitary prolactin storage. Melatonin 
increases pituitary prolactin secretion in cyclic mammals. Melatonin does not directly 
affect prolactin release, but inhibits the release of dopamine from the preoptic area of the 
hypothalamus. 17B-estradiol blocks melatonin's inhibition of dopamine. Doparnine's 
inhibitory action infuences prolactin secretion. Therefore, indirectly, melatonin 
supplements in ageing individuals will raise the level of prolactin [Fig. 2]. However, in 
younger individuals, melatonin decreases prolactin production (106). Melatonin does not 
affect secretion nor storage of prolactin in the median eminence(2). 
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When luteinizing honnone-releasing honnone(LHRH) is supplemented, cyclic and 
acyclic rats showed significant increase in luteinizing honnone secretion, but only acyclic 
rats exhibited increased FSH secretion(2). This results from different honnonal control 
mechanisms for the two gonadotropins. It, also, appears that the control mechanisms may 
change in response to increased age, resulting in or as a result of decreased fertility or 
complete loss offertility. Melatonin supplements neutralized the increased gonadotropin 
release stimulated by LHRH additions(2). 
LH secreting cells, gonadotropes, in the pars tuberalis of mammals have a 
distribution corresponding to LHRH neuron terminals in the ME (IO). LH inhibits its own 
release in a short-loop feedback by diffusing from the pars tuberalis into the ME and 
inhibiting LHRH release (81). This inhibition may be a direct action ofLH on LHRH 
neuron terminals or an indirect action via other neuronal terminals. 
Melatonin receptors in mammalian brains are found in the highest concentrations in 
the pars tuberalis (135). This leads to the conclusion that melatonin may inhibit LH release 
in the pars tuberalis of the pituitary gland. The endocrine secretory cells of the pars 
tuberalis undergo seasonal fluctuations in their histology reflecting reproductive cycles. 
These fluctuations may result from variations in pineal melatonin release promoting 
seasonal breeding. 
Melatonin stimulates ME LHRH secretion. Melatonin acts on receptors found on 
gonadotrope cells in the pars tuberalis, inhibiting LH release (81 ). As LH inhibits ME 
LHRH secretion, melatonin indirectly increases ME LHRH secretion by blocking the LH 
short-loop feedback. Melatonin may inhibit LH release by inhibiting adenylate cyclase in 
gonadotropes, producing a reduction in cAMP. Significant melatonin receptor 
concentrations in the pars tuberalis are dependent on estrogen (62). When estrogen 
concentrations are low, such as after menopause; pituitary melatonin receptor 
concentrations decrease, and the inhibition ofLH release is lost. Therefore, low estrogen 
concentrations can lead to a decrease in ME LHRH release, although LH levels will 
remain high. Melatonin is intrical to the sensitivity ofLHRH release [Fig. 3]. 
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These age related changes in the hypothalamic-pituitary functions of the body 
affect reproductive hormones and, thus, reproductive viability. Deficient LHRH, or 
response and sensitivity to it, has been linked to decline in reproductive function(73). Age 
related changes in the anterior pituitary also produce a decline in reproductive function 
through gonadotropin secretion. Acyclic rats' anterior pituitary, when transplanted on the 
median eminence of cyclic rats, can not support cyclic secretion of gonadotropins(85). 
These cyclic rats show no loss of reproductive function when the anterior pituitary 
transplant is taken from another cyclic animal. These changes in the pituitary and 
hypothalamus coincide with the gradual decreased secretion of melatonin from the pineal 
gland, beginning in middle age. 
Pituitaries of acyclic animals are still responsive to exogenous LHRH and 
melatonin. The altered state of the anterior pituitary results from changes in endocrine 
status, not simply chronological age. The acyclic, transplanted anterior pituitary glands 
that could not support normal estrous cycles had already been altered by the acyclic 
animals endocrine cycle. These glands were not responsive to regeneration when 
transplanted into a cyclic animal's hypothalamic-pituitary reproductive feed-back loop. 
There is no research available to determine the results of additional melatonin supplements 
to these cyclic-transplant animals with regard to acyclic anterior pituitary regeneration. 
The biosynthetic mechanisms to produce gonadotropins and prolactin are 
unaffected by chronological age. The secretory response is altered with increasing age and 
relative to decreasing melatonin concentrations. Aged animals exhibit higher 
concentrations of circulating gonadotropins. The addition of melatonin supplements to the 
diets of ageing animals restores the concentrations of melatonin to levels exclusively 
secreted by the pineal gland in youth. This lowers gonadotropin levels by inhibiting the 
response of the gonadotropin secretion to LHRH. 
23 
There is no change in prolactin, nor LH storage when melatonin is supplemented, 
although melatonin decreases the storage levels of FSH in young animals. This is the same 
result observed as animals age without melatonin supplements. Melatonin lowers 
gonadotropin secretion through LHRH, but it has no affect on LH storage, it acts the 
opposite, similar to age, as would be expected by lowering FSH storage in cyclic animals 
and raising FSH storage in acyclic animals. When storage is decreased, increased 
secretion would be expected. As storage is increased, a decrease in secretion would be 
expected. This counterintuitive fact would be an excellent area for further research to 
determine melatonin's biological interactions with gonadotropin receptors. 
Chronological ageing decreases the hypothalamic regulation ofLH(87). The body 
is capable of producing youthful levels ofLH in advancing age, however this is prevented 
by the endocrine system. GnRH controls the release of LH from the pituitary. The 
expression of the GnRH gene is suppressed with increasing age. LH also becomes less 
responsive to GnRH with age. Increased levels of circulating melatonin increases the 
expression of the GnRH gene and the responsiveness ofLH to GnRH(l06). Melatonin 
supplements indirectly decrease the surge in LH that foreshadows menopause, thus 
delaying the onset of menopause. 
A principle interest of melatonin research has been with regard to the female 
reproductive cycle. As melatonin is a tropic hormone, it has significant affects on 
reproductive cycles, as they are based on multiple hormones. The pituitary-hypothalamic 
axis is the center of regulation for each cycle. 
In ageing females, melatonin's effects are complex. If melatonin is supplemented in 
premenopausal individuals, it can delay menopause. 
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Women are delaying having children until later in their lives. As reproductive 
fertility is almost completely lost ten years before menopause, women must race their 
biological clocks. They gamble with increased risks of miscarriages or Down's 
syndrome.(76) With recent changes in societal pressures, women must balance these risks 
of abnormality or infertility with establishing a career before having children. Ten percent 
of women start menopause before they are forty-five.(76) These ten percent could 
completely lose their fertility by the age of thirty-five. These pressures are evident in the 
increased reliance on fertility drugs. Meredith contrasted three methods to delay 
menopause.(76) Caloric restriction is the first. As this restriction must be chronic, it is 
obviously unfeasible. It is interesting to note that caloric restrictions extend human 
lifespans and the intestine is one area that produces melatonin in the human body. 
Research should explore the link between caloric restrictions and higher levels of 
melatonin in greater depth. Melatonin may also regulate the patterns we develop regarding 
hunger and meal times. 
The second method to delay menopause is long-term progesterone 
supplementation(61). The progesterone is slowly administered from silastic implants. 
Progesterone supplementation has undesirable side affects, including bleeding irregularities 
(117). Progesterone supplementation and caloric restrictions cause the nervous system, 
hypothalamic-pituitary axis, to decrease the amount ofLH secreted with age(61). Both 
methods also reduce the age related loss of primordial follicle cells. With more follicle 
cells, inhibin concentrations remain high enough to inhibit FSH secretion. 
The final method to delay menopause is through melatonin supplements. Nighttime 
supplementation of melatonin had no effect on the number of primordial follicle cells(76). 
Melatonin is a tropic hormone and, therefore, is the most natural and noninvasive way to 
delay menopause. Melatonin supplements replace the reduced levels of melatonin secreted 
by the pineal gland with age. This allows pituitary secretion of gonadotropic hormones 
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similar to levels found after puberty and before menopause. There are few side effects, 
although Pierpaoli found an increased occurrence of ovarian tumors exclusively in one 
species of mice, C3H/He.(90) Nighttime supplementation of melatonin delayed menopause 
by regulating the length of estrous cycles through gonadotropins late in reproductive 
life.(76) Twenty-four hour supplementation did not affect the reproductive lifespan (76). 
After menopause, melatonin exhibits different reactions on the 
hypothalamus-pituitary axis. Post menopausal ageing decreases the pituitary's 
gonadotropic regulation. FSH and LH levels remain much higher than in youth. LH 
becomes less responsive to GnRH with increasing age after menopause. 
Estradiol and progesterone levels decrease in women after menopause. LH and 
FSH plasma levels are elevated in elderly women. 
Melatonin supplements have been shown to increase the LHRH mRNA levels 
significantly in older individuals(IOI). A decrease in either LHRH or the pituitary's 
response to LHRH begins the decline in reproductive function and a LH surge. 
The inhibitory affect of melatonin on the secretion of pituitary hormones is 
dependent on the endocrine status and age of the animal(IOO). 
Prepubertal males' androgens exhibit a negative feed-back on hypothalamus 
activity, specifically gonadotropin secretion. Testosterone propionate inhibits LH 
secretion. The sensitivity of this feed-back loop decreases after puberty, which it 
initiates(72). Plasma LH concentrations remain similar after puberty. With the decreased 
sensitivity to androgens, higher concentrations of testosterone are required to maintain the 
same levels ofLH. Testosterone exhibits a positive feed-back effect on prolactin in 
prepubertal males, but not in adult males(3 l ). 
As menopause is not an event in the male reproductive life, research regarding 
melatonin's effects on the neuroendocrine-reproductive axis are tailored towards puberty, 
in order to diagnose and treat problems that develop at this age. This research focuses on 
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the development of sexual organs, starting with the fetal endocrine system. The negative 
feed-back response ofLH to testosterone begins in the fetus. This feed-back becomes less 
sensitive, initiating puberty by requiring higher concentrations of plasma testosterone to 
maintain the same plasma concentrations to prepubertal LH levels, and coinciding with an 
increase in GnRH receptors in the pituitary gland(31 ). As testosterone serum 
concentrations rise, they inhibit the hypothalamic release of GnRH(31 ). Higher 
concentrations ofGnRH receptors are found in the pituitary, with puberty, in order to 
maintain proper LH plasma concentrations(31 ). When melatonin is administered to 
prepubertal males, the negative feed-back testosterone propionate exerts on LH is 
inhibited(31 ). 
Melatonin reduces the negative feed-back affects produced by testosterone 
propionate on LH, but lowers the basal levels ofLH in prepubertal males. Melatonin 
inhibits GnRH release, hypothalamic-pituitary axis sensitivity to gonadotropins and the 
reproductive cycle, delaying puberty. 
After puberty, which results in lower plasma concentrations of melatonin and 
higher plasma concentrations of testosterone, additional melatonin supplements raise the 
basal concentrations of plasma LH. This is the same result as seen in females after puberty. 
Melatonin supplements continue to inhibit the affects of testosterone propionate on LH 
secretion, as found before puberty. 
Melatonin lowers the plasma LH concentrations before puberty even though it also 
reduces the inhibition of testosterone propionate on LH. Melatonin lowers the plasma 
levels ofLH before puberty by acting on the hypothalamus, not the pituitary. This is 
accomplished through the decrease of GnRH release from the hypothalamus. After 
puberty, there is less significance regarding melatonin's reduction of hypothalamic GnRH 
release because the GnRH receptor concentration increases in the anterior pituitary. 
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Pituitary FSH secretion is inhibited by testosterone to a lesser degree than LH, as 
gonadotropin release is regulated by different mechanisms( 40). FSH secretion is not only 
controlled by testosterone, but also by inhibin B(l28). Before puberty, melatonin lowers 
basal plasma FSH concentrations. Although, unlike LH, melatonin has little affect on the 
negative feed-back exerted by testosterone propionate on FSH prior to and after 
puberty(3 l ). 
The reduced basal plasma concentrations ofFSH due to melatonin do not change 
with the addition of testosterone propionate(3 l ). These basal concentrations are lower 
than the inhibitory effect testosterone propionate produces without melatonin. 
Melatonin lowers the basal plasma concentrations of both gonadotropins prior to 
puberty  In this manner, melatonin supplements can delay the onset of puberty. Basal 
prolactin levels are at the highest plasma concentrations at puberty. Before and after 
puberty, testosterone exhibits a stimulatory affect on prolactin. During puberty, 
testosterone's stimulatory affect on prolactin is most pronounced. Melatonin reduces the 
basal plasma concentrations of prolactin before puberty and during puberty. Melatonin 
reduces testosterone's stimulation ofprolactin secretion(3 l). Melatonin's reduction of 
testosterone's response on prolactin reduces in potency with age, from birth until death. 
Testosterone's stimulation ofprolactin is at its maximum during puberty. Melatonin 
greatly reduces this stimulation of prolactin secretion at puberty. 
Elderly men exhibit low plasma testosterone concentrations in the morning(l32). 
In the afternoon, the plasma testosterone levels of elderly men are similar to those of 
younger men. As melatonin production decreases with age and is at its highest levels in the 
early morning, melatonin may not only amplify the tropic affects of testosterone, but also 
contribute, with short duration, to its production or secretion. 
The rhythm and concentration of melatonin secretion was disturbed in 
hypogonadal male patients (66). Testosterone replacement normalized pineal function  
28 
Melatonin affects gonadotropin and gonadal steroid secretion. In addition to melatonin's 
influence on the pituitary gland, human granulosa cells (138) and prostate cells (39) also 
have melatonin receptors. Recent studies have suggested that melatonin secretion may be 
influenced by gonadotropins and gonadal steroids. LH, FSH, estrogen and androgen 
receptors are present in the pineal gland (65)  As the pineal gland calcifies, melatonin 
secretion decreases, yet gonadotropin and gonadal steroid receptors persist in the pineal 
gland with age. Gonadotropin receptors vary in concentration with season, expressing a 
ten- fold increase in winter. Seasonal changes in photoperiod duration produce these 
changes. Daily light-dark cycles only produce changes in FSH pineal receptor 
concetrations, with a higher concentration at night. Plasma concentrations of 
gonadotropins do not change between seasons. The seasonal concentration changes in 
pineal gonadotropin receptors in the pineal is similar to the winter increase in melatonin 
secretion, storage and SCN vasopressin cell concentrations (65). Gonadal steroids appear 
to only influence melatonin release at night (113). Although, this time- related effect does 
not change gonadal steroid pineal receptor concentrations. It may be the combination of 
gonadal steroid receptor binding and the influence gonadal steroids have on gonadotropin 
secretion on the hypothalamus- pituitary- gonadal axis. Gonadal steroids and 
gonadotropins effect the peptide and indole secretions in the pineal gland (44). These 
peptides and indoles may also have an influence on melatonin synthesis and secretion. 
TACHYKININS 
Tachykinins are bioactive peptides that stimulate smooth muscle. Although they 
have widespread localizations, they are predominantly concentrated in the respiratory and 
gastrointestinal tracts. Tachykinins are vasodilators (96) and influence the secretion of 
endocrine glands. This regulation of blood supply modifies tachykinin concentrations in a 
feedback loop with reproductive hormones. Tachykinin's paracrine activity acts on the 
hypothalamus, anterior pituitary, gonads and pineal gland, modulating the 
hypothalamo-pituitary-gonadal axis (23 ). 
Four precursor proteins produce the tachykinins. These proteins are the products 
of two genes, preprotachykinin A and preprotachykinin B (23). Preprotachykinin A 
encodes for substance P (SP), neuropeptide K (NPK), neurokinin A (NKA), and 
neuropeptide y (NPG). Preprotachykinin B encodes for neurokinin B. Two of the four 
precursor proteins contain the complete sequence of SP and NKA, formation of each 
depending on RNA splicing and posttranslational processing (23). As a result, SP and 
NKA are generally colocalized. 
Tachykinins have three subtypes of receptors: SP targets NK-1 receptors, NKB 
targets NK-3 receptors and NKA, NPK and NPG target NK-2 receptors (22,27). 
Tachykinins interact with all three receptor types, as they display poor selectivity (126). 
NK-2 receptors are generally located in the peripheral nervous system (101), while NK 1 
and NK-3 receptors are distributed in the central nervous system (26). 
Successful reproduction depends on an interrelationship between the hypothalamus 
and pituitary gland, and an interaction of the pituitary gland and gonads via gonadotropic 
hormones (23). Reproductive hormones and tachykinins modulate the regulation of the 
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hypothalamus, the anterior pituitary, and the gonads (the three levels of the reproductive 
system). 
The hypothalamus has an abundance of SP, NKA and NKB neurons; including the 
preoptic area, ventromedial nucleus, infundibular nucleus and arcuate nucleus. The 
preoptic nucleus influences the sexual behavior of male rats, as male rats have double the 
tachykinin concentrations offemale rats (23). Large bundles oftachykinin-positive nerve 
fibers are found in the anterior suprachiasmatic nucleus, connecting it with 
tachykinin-containing retinal ganglia cells (93). This is also the first step in stimulating the 
pineal production of melatonin. 
The ventromedial nucleus of female rats is responsible for sexual receptivity. The 
concentration of tachykinins in the ventromedial nucleus of male rats remains constant 
with castration. Female rats' tachykinin concentrations increase with estrogen exposure 
and decrease with ovariectomy (100). Nerves containing tachykinin transcripts and 
estrogen receptor rnRNA, in the infundibular nucleus, hypertrophy after menopause (23). 
These nerves may help regulate estrogen and gonadotroph negative feedback. The arcuate 
nucleus, a center of neuroendocrine control, receives a large tachykinergic innervation 
from the preoptic area (98). The arcuate nucleus also has the highest tachykinin 
concentration of the hypothalamus (67). The SCN is connected to both the retina and 
arcuate nucleus via dense tachykinergic nerve fibers. 
The tachykinins modulate the secretion of hypothalamic hormones by stimulating 
neurosecretory terminals, which release the hormones into the portal vessels (19). 
Vasopressin and oxytocin release may be modulated by tachykinin receptors in the 
supraoptic and paraventricular nuclei. Tachykinergic neurons and magnocellular neurons 
in the supraoptic and para ventricular nuclei have synaptic contacts ( 19). 
Tachykinins modify gonadotropin secretion via hypothalamic GnRH release. Thus, 
gonadal steroids may modulate tachykinin concentrations in the hypothalamus via their 
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negative feedback loop with GnRH (19). Orchidectomy in rats decreased the median 
eminence, paraventricular nucleus, arcuate nucleus (75) and hypothalamic NKA 
concentrations (35). Testosterone, dihydrotestosterone and extradiol treatments reversed 
the NKA declines seen in each of the previous experiments, returning NKA concentrations 
to the level of controls, or higher, in the central nervous system. In addition to the 
regulation of tachykinins that testosterone and estradiol exhibit, GH may also alter 
tachykinin concentrations ( 42). 
The anterior pituitary gland contains a lower concentration of tachykinins than the 
hypothalamus (46). Male rats' anterior pituitary tachykinin concentrations are higher than 
female rats' concentrations (31 ). Although this observation was based on a mean 
measurement, tachykinin concentrations fluctuate in the anterior pituitary of female rats 
during the estrous cycle ( 46). Tachykinin concentrations in the anterior pituitary are 
highest when estradiol serum levels are lowest. Estrus and tachykinin concentrations are 
lowest when estradiol serum levels are highest, proestrus. The estradiol suppression of 
tachykinins in the anterior pituitary is the reverse of the estradiol influence on the 
hypothalamus. Ovariectomy resulted in a rise in anterior pituitary tachykinin 
concentration, and estradiol treatment reversed the increase ( 46). Male rats, also, 
displayed an anterior pituitary tachykinin concentration increase with orchidectomy, which 
was blocked with testosterone replacement treatments (38). Additionally, thyroid 
hormones inhibit tachykinin concentrations in the anterior pituitary gland (72). 
Anterior pituitary glands have lower concentrations of tachykinins than 
hypothalamus glands, but the tachykinin levels are more sensitive to environmental 
photoperiods. The Siberian hamster, as a species, is extremely sensitive to environmental 
photoperiods, and possesses a relatively higher concentration of tachykinins in its anterior 
pituitary, with regard to other rodent species (30). Shortened and lengthened photoperiods 
increased tachykinin concentrations in the anterior pituitary of the Siberian hamster. The 
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animals exposed to the shorter photoperiods had the largest increase in tachykinin 
concentrations. Gonadal regression occurred in animals exposed to altered photoperiods. 
In females, the decrease in gonadal hormones resulted in the increase in anterior pituitary 
tachykinin concentrations. In males, decreased thyroid hormones resulted in the increase 
of anterior pituitary tachykinin concentrations ( 40). The thyroid regression resulting from 
the altered photoperiod would also contribute to the tachykinin increase in females, as this 
increase is sufficiently strong to offset the loss of tachykinin stimulation from testosterone 
in gonadally regressed animals. 
Substance P, NKA and NPK tachykinins are found in the pineal gland (32,55). 
Tachykinins in the pineal gland are inhibited by testosterone. Castration produces � 
increase in pineal tachykinin concentrations, and these concentrations return to normal 
with testosterone replacement therapy (32). In female rats, ovariectomy resulted in a 
decrease in pineal tachykinin concentrations. Superior cervical ganglionectomy, the main 
noradrenergic pineal innervation, resulted in an increase in pineal tachykinin 
concentrations. Although this innervation, the final step relaying circadian rhythm to the 
pineal, produces an inhibitory effect on pineal tachykinin concentrations, and pineal 
tachykinin concentrations decrease with dark photoperiods in female rats, no significant 
circadian rhythm of pineal tachykinin concentrations was found (32). The decline in pineal 
tachykinin concentrations in female rats during dark photoperiods may be an indirect 
response to the influence gonadal hormones exhibit on tachykinin concentrations. 
Tachykinins increase the prolactin secretion, particularly during proestrus surges, 
in the presence of a significant estrogen concentration (23). When an antiserum to NKA 
was injected during diestrus II, proestrus prolactin secretion was significantly decreased 
(94). Hernipituitaries incubated with an anti-NKA serum had reduced basal and NKA 
stimulated prolactin secretion in intact rats (95). The same results could not be reproduced 
with ovariectornized rats, lacking estrogen. Antiserum to NKA also reacts with NPK and 
33 
NPG. In addition, antiserum to NKA (96) and anti-SP serum (24) reduced the prolactin 
surge resulting from suckling. Henriksen found tachykinins to stimulate prolactin secretion 
in anterior pituitary cells ( 49). The tachykinin stimulation of prolactin release may act 
directly on the anterior pituitary, or it may be directed at blood-brain barrier deficient 
hypothalamic neurons. Tachykinins may alter the release of neurotransmitters from these 
neurons, affecting prolactin secretion in the anterior pituitary (23). Additional research is 
needed to determine if tachykinins affect prolactin releasing hormone in the hypothalamus. 
NKA may stimulate prolactin secretion by activating phosphoinositide metabolism 
(69). NKA activates the receptor-mediated hydrolysis ofphosphoinositides in the anterior 
pituitary, which stimulates prolactin and LH secretion (74). NKA intracerebroventricular 
injections increased proopiomelanocortin (POMC) mRNA expression 48% in the arcuate 
nucleus (69). Opioids stimulate prolactin secretion and inhibit LH secretion (23). NKA 
activation of POMC neurons may influence an interrelationship between tachykinins, 
prolactin and gonadotropin release. 
NKA activation of the opioid system may decrease LH secretion by inhibiting 
GnRH release at the hypothalamic level (23) The NKA inhibition ofLH secretion may 
also be a result of the tachykinins suppression of neurotransmitters at the hypothalamic 
level, or a combination of the two mechanisms (23). When the third ventricle of 
ovariectomized rats is injected with NKA, plasma LH concentrations decrease (23). When 
injecting an antiserum to NKA with cross-reacting activity for NPK and NPG into the 
third ventricle, serum LH concentrations increase in ovariectornized rats. Without the 
cross-reacting activity for multiple tachykinins, antiserum to NKA will not elicit a change 
in plasma LH concentrations (94). This appears contradictory to experiments resulting in 
decreased LH plasma concentrations when NKA is injected into the third ventricle. 
Intraventricular injection ofNPK produced a significant reduction in plasma LH, and NPG 
intraventricular injections reduced plasma LH concentrations to a lesser extent. The LH 
surge produced by progesterone could also be inhibited by NPK. The three tachykinins, 
working together, produce a strong physiological inhibition of plasma LH secretion. 
Perhaps the cross-reactivity is important because NKA, NPG and NPK share NK-2 
receptors. A general NK-2 receptor agonist was shown to inhibit basal hypothalamic 
GnRH secretion (57). 
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Male rats intraventricularly injected with NKA, NPG or NPK had signifcant 
increases in serum LH (57). When orchidectornized, the tachykinin intraventricular 
injections suppressed LH serum concentrations. As in females, NPK was the most potent. 
NPK and NPG stimulate LH release at the pituitary level of intact male rats. An NK-2 
antagonist stimulated LH, but not FSH, secretion from the pituitary (20), but inhibited the 
LH and FSH response to GnRH (23). NPK was unable to inhibit LH release when injected 
with NMDA. Tachykinin inhibition ofLH release appears to be related to a suppression of 
neurotransmitters. 
Tachykinins generally suppress LH release at the hypothalamic level and stimulate 
release at the pituitary level. The actions of tachykinins are affected by gonadal hormones, 
which can negate the effects oftachykinins. Tachykinins can not stimulate LH release at 
the pituitary level without the presence of testosterone (57). Tachykinins exert an effect on 
the hypothalamus-pituitary axis at multiple points. They react with GnRH neuron cell 
bodies in the preoptic area, median eminence nerve terminals and neurotransmitter 
suppression (23). These multiple points of influence, combined with gonadal hormone 
modification of tachykinin effects, create an intricate regulation of the endocrine system 
with multiple feedback loops. 
Tachykinins help regulate hormone secretion in gonads. SP is found in Leydig cells 
(19) and tunica albuginea nerve fibers (124). The testis have also exhibited the ability to 
synthesize SP, NKA, NPK and NPG (23). SP inhibits testosterone release by Leydig cells 
(5). NPG and NKA stimulate estradiol secretion from Sertoli cells. This increase in 
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estradiol results from an increase in testosterone secretion, enzymatically being 
synthesized into estradiol (23). Iftachykinins stimulate Sertoli cell secretions of 
testosterone, they may stimulate the Sertoli secretions of other factors, influencing the 
hormone secretion of Leydig cells. The tachykinin inhibition of testosterone release from 
Leydig cells occurs in both long and short photoperiods (5), although SP reduced the 
Leydig cell LH receptor concentrations during short photoperiods (58). 
Ovarian SP concentrations dramatically rise after puberty (84). SP effects on 
ovarian hormone release differs before and after puberty. In 15 day old hamsters, SP 
stimulated estradiol release, but not progesterone release. Adult hamsters' ovaries 
incubated with SP had stimulated progesterone release, and inhibited estradiol release (5). 
Melatonin is a tropic hormone, infuencing reproduction with its affects on 
gonadotropic hormones, estrogen and testosterone feedback loops, prolactin and GH. 
Tachykinins also help maintain the hormonal balance needed for reproduction. Both 
melatonin and tachykinins act on the hypothalamo-pituitary-gonadal axis to achieve this 
hormonal control. Tachykinins' primary influence on the hypothalamo-pituitary-gonadal 
axis is as vasoactive peptides. They can alter the blood flow to neuroendocrine structures, 
including the pineal gland. Tachykinins also display paracrine and autocrine activity. This 
allows for specific neuronal effects, such as stimulating GnRH or prolactin secretion (23). 
Tachykinins are essential to anterior pituitary and possibly hypothalamic hormone release. 
Tachykinins stimulate LH and prolactin secretion from the anterior pituitary gland. 
Gonadal steroids affect the tachykinin concentrations in the pineal gland (23). Perhaps 
tachykinins have a more direct mode of regulation on melatonin secretion, production and 
feedback loops than vasoregulation. 
The hypothalamus, median eminence, pituitary gland and gonads are coordinated 
through complex nerve and hormone feedback loops. Tachykinins and melatonin affect 
similar hormones, infuencing their storage and secretion. Melatonin and tachykinins 
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innervation is also similar. The SCN receives innervation from the retina that, once 
processed, will eventually reach the pineal gland. The anterior SCN also has large bundles 
of tachykinin-positive nerve fbers, connecting it to the retina. The preoptic area projects a 
tachykinin innervation to the arcuate nucleus. The arcuate nucleus, the highest tachykinin 
concentration in the hypothalamus, is connected to the SCN. It may be possible that 
neuroendocrine information is combined with photoperiod signals, processed in the 
arcuate nucleus and sent to the pineal gland for appropriate release of melatonin. Other 
nuclei may also be connected to the SCN for this purpose. The infundibular nucleus nerves 
containing tachykinins, hypertrophy after menopause. Additional research exploring the 
possible coordination of tachykinin and photoperiod influe11ces on infundibular nucleus 
actions affecting melatonin regulation is needed. 
IMMUNE SYSTEM 
If age is a result of the deterioration of the immune system, or vice versa, 
the thymus must be viewed as an important factor. The thymus is replaced by fatty tissue 
with age, until it hardly exists as a functional gland. Regelson has shown melatonin to 
increase the weight of the thymus, restore the production of T cells from the thymus and 
restore the antigen response ofT cells (92). These results appear amazing, but Regelson 
produced more incredible results. He restored a thymus gland, ravaged by time, to its 
youthful, functional ability by transplanting an active pineal gland on to this thymus gland. 
Preventing the nighttime surge of melatonin caused a reduction of antibody 
production in mice. Restoring the melatonin surge in the same mice resulted in a return of 
antibody levels to normal (122). Melatonin production decreases with age. High fat diets 
reduce T cell function, and insufficient vitamin C leads to lower T cell numbers. Smoking 
tobacco decreases the available vitamin C to the body. Older smokers with fatty diets 
frequently have many medical debilitations. Certainly, a contribution to these ailments is 
the accelerated decline in their immune systems. Increasing health in the elderly should 
include a healthy diet, not smoking and melatonin supplements to maintain a strong 
immune system. 
Sleep deprivation produces a decline in T cell function (92). The immune system 
deterioration directly refects ageing. The thymus shrinks and T cells become less effective 
as an individual ages. Particularly, suppresser T cells become almost ineffective. This 
allows antibodies to destroy valuable, non-antigen cells in the body. 
Melatonin increases the antibody response when supplemented after initial 
exposure to antigens. Regelson provoked an immune response in mice by exposing their 
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immune system to sheep blood, after an initial exposure to produce antibodies (92). Their 
immune response was increased when melatonin was supplemented for one week after the 
initial exposure. Regelson raises the question, would melatonin supplements increase the 
effectiveness of childhood vaccinations? Although possible, this may not be necessary, as 
melatonin levels are highest prior to puberty 
Many cells produced by human lymphoid organs, i.e., thymus, spleen and blood, 
have melatonin specific membrane bound receptors with an affinity between O .1-1 nM Kd 
(13). Melatonin, at its physiological concentration, appears to partially regulate the 
immune system by directly regulating immunocompetent cells (136). Melatonin receptors 
have also been found on the cell membranes of the retina, SCN, pars tuberalis, thalamus, 
subiculum and area postrema (137). Melatonin is an important common signal molecule 
with receptors on both neuroendocrine and immune cells. This simultaneous influence on 
both systems allows melatonin to synchronize the endocrine and immune system, helping 
them to work in concert. 
Human blood lymphocytes have two different melatonin specific binding sites (16). 
One receptor is high affinity, while the other is low affinity. The high affinity receptor has 
a 5-50 times lower affinity for melatonin than the receptors found in the .ME, SCN, area 
postrema, and Harderian gland (16). Although melatonin exhibits a relatively weak affinity 
for lymphocytes, high affinity lymphocyte receptors have a Kd value slightly higher than 
serum melatonin concentrations at their physiological peak, at night (16). Therefore, 
lymphocytes may only be influenced by melatonin at night. Lymphocytes appear to be the 
only leukocyte with the high affinity melatonin receptor. The receptors found in 
granulocyte cells are similar in affinity to the low affinity receptors of lymphocytes. For 
example, neurtophils have a melatonin receptor with an affinity in the uM range (16). 
Often, melatonin serum concentrations are too low to bind to the high affinity lymphocyte 
receptor. With 1000 times lower affinity, it is unlikely that the granulocytes are directly 
influenced by physiological concentrations of melatonin. This does, however, allow the 
option of influencing granulocytes through prescription doses of melatonin. Further 
research to discover the purpose of these melatonin receptors on granulocytes and what 
effect high doses of melatonin have on the high affinity recetors would be valuable. 
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Melatonin binding sites have been found in spleenocytes ( I 02) and thymocytes 
(138). These binding sites are considered high affinity with a Kd of0.34 and 1.72 nM, 
respectively (16). The 1. 72 nM Kd affinity of melatonin receptors in the thymus is 
relatively strong. Melatonin, at physiological serum concentrations, enhances the immune 
system by inhibiting the influence of corticosterone (I 39). Although, this result was only 
exhibited when the animal was frst infected with T-dependent antigens (16). This 
decisively proved that melatonin's influence on the thymus existed. Melatonin was later 
shown to increase the affinity and decrease the concentration of adrenal steroid receptors 
in the thymus (16). This solidified melatonin's role as an inhibitor ofimmunosuppressive 
agents, such as steroid hormones. The thymus receptors for steroid hormones are a site of 
interaction between the immune and endocrine system. Melatonin and steroid hormones 
interact on thymocytes and influence the extent and duration of the immune response (86). 
The number and affinity of melatonin receptors in the thymus changes with age 
(I 5). The pineal gland does not fully develop until the second week after birth ( 42). This 
results in a low serum concentration of melatonin. The melatonin receptors on thymocytes 
increase their binding capacity via an increase in receptor numbers, not affinity, in order to 
compensate. Melatonin binding to thymocyte receptors is higher in newborns than adults. 
Pinealectomy in neonatals reduces thymus size and immune function (16). Melatonin is 
intricately involved in the maturation and function of the thymus and immune system. 
The development of the pineal gland during the first two weeks after birth may be 
affected by an infant's first exposure to direct light. As the pineal develops, melatonin 
serum concentrations increase. This increase reduces the negative feedback which was 
increasing the concentration of melatonin receptors on the thymus (16). The loss of 
receptor concentration is seen as the thymus and pineal gland develop. 
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When animals are exposed to constant light, an increase is seen in melatonin's 
binding to spleenocytes (102). This increase in receptor concentration, again not affinity, 
may allow light to influence melatonin's regulaton oflymphoid cells (16). As light levels 
increase, melatonin concentrations decrease and receptor binding increases. 
Recently, the hypothesis for the signal transduction pathway for melatonin in 
human lymphocytes and its affect on cAMP and cGMP production was solidified at The 
University of Seville in Spain (16) Melatonin was found to be unable to activate cAMP 
production Vasoactive intestinal peptide (VIP) can activate cAMP production in human 
lymphocytes. When melatonin, at physiological concentrations, was combined with VIP, 
an increase in cAMP production was observed exceeding the production of VIP alone. 
This effect was not seen with any other peptide in the secretion-VIP group. Both VIP and 
melatonin may be needed to regulate cAMP production in human lymphocytes, thus 
infuencing the immune system, as the effect is seen at physiological concentrations of both 
melatonin and VIP. A similar result was observed on spleenocytes when melatonin was 
combined with forskolin (102). Alternatively, when pharmacological doses of melatonin 
were administered to spleenocytes, cAMP production was inhibited. 
Melatonin, alone, directly increases the cGMP production in human lymphocytes 
up to 10 uM (136). GTP inhibited the binding of melatonin to its membrane receptors. 
ATP, CTP and UTP did not affect melatonin binding (16). This affirmed the conclusion 
that melatonin receptors are coupled to G-proteins in human lymphocytes. 
Thyrotropin (TSH) is secreted with a circadian rhythm and peaks nocturnally. This 
cyclic rhythm is lost in aged individuals, in whom TSH secretion follows an increasingly 
linear pattern. T4 is not secreted with a circadian rhythm, although its secretion and 
synthesis is controlled by TSH. T 4 secretion produces a negative feedback control on 
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TSH. This interdependence would infer a circadian rhythm for T4 similar to TSH 
secretion, but these secretion patterns are complicated by thyrotropin-releasing hormone 
(TRH). TRH influences the hypothalamic release of TSH. 
CANCER 
Patients with unoperated primary prostate cancer (malignant) express different 
hormonal concentrations. TSH secretion is depressed with a further depression at 19:00 
hours ( 13 ). The circadian rhythm of secretion is also lost, as in patients with benign 
prostate hyperplasia The T4 plasma concentrations are slightly higher in men with primary 
prostate cancer than in men with benign prostate hyperplasia This T 4 elevation inhibits 
TSH production as a result of the increased negative feedback on TSH (13)  
Many elderly men develop benign prostate hyperplasia, and the risk of developing 
malignant cancer increases with age. A current diagnostic tool to detect benign prostatic 
hyperplasia or prostatitis is the prostate-specific antigen test (PSA). A high PSA result 
may lead to a biopsy and eventually an ambiguous Gleason score. Research is needed to 
determine if melatonin would be a beneficial treatment to inhibit a slow growing tumor. 
With the uncertainty regarding diagnosis of prostate cancer in men, melatonin 
supplementation may be a more beneficial, conservative treatment, alleviating the 
drawbacks of current aggressive treatments. 
Melatonin plasma concentrations are lower in the elderly, but aged men with 
primary prostate cancer express even further depressions in melatonin secretion with an 
,almost total loss of circadian rhythm (13 ). As the tumor increased in mass, the melatonin 
plasma concentrations continued to decrease. Melatonin secretion declines with age, but 
the large decreases of melatonin seen in cancer patients is not related to age. Patients with 
benign tumors expressed higher melatonin concentrations than patients of the same age 
with malignant tumors. The stage of a malignant tumor directly influences the depression 
of melatonin production and secretion (13). Melatonin concentrations in patients with 
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benign lesions are influenced by the individuals age, independent of the tumor. This 
conclusion holds true for breast cancer, as well as prostate cancer. Next to lung cancer, 
these are the most abundant cancers. It is logical to conclude that malignant tumors cause 
disruptions in hormonal concentrations  Many cancers are hormone dependent. Breast 
cancer growth is estrogen dependent. As a result, estrogen levels are elevated in patients 
with breast cancer. 
As melatonin levels are significantly lower in cancer patients, malignant tumors 
directly infuence pineal secretion or production of melatonin (13). Melatonin, in tum, 
affects the concentrations of other hormones via its control of hypothalamic hormonal 
release. The decreased TSH levels may be a result of decreased melatonin concentrations 
producing a decrease in TRH stimulation. This leaves the increased T4 plasma 
concentrations in cancer patients unexplained, although high T 4 levels further depress 
TSH secretion. 
As a malignant tumor increases in size, melatonin production is increasingly 
inhibited. This negative feedback could account for the progression of malignant tumors. 
Melatonin supplements boost the immune system by restoring T cells to their most 
effective levels (92). With lower melatonin levels, a weakened immune system would be 
less effective against malignant tumors. 
Generally, the suppresser T cells are less effective at recognizing self from non-self 
tissue. This causes many autoimmune diseases associated with age. The GH decrease seen 
with age causes both a decrease in the immune system and a change in protein synthesis. 
This slight change in the way a protein is composed may be why T cells are less effective 
at recognizing which tissues are self and which are foreign (92). 
Melatonin is actively being researched as a drug to slow ageing and return 
hormone balances to youthful standards. In this respect, melatonin may be able to do more 
than help treat disease. Melatonin may be a way to prevent disease. The research strongly 
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suggests melatonin's value may primarily lie in preventing autoimmune diseases associated 
with age, for example, rheumatoid arthritis (92). Although this research is promising, due 
to the relatively long life of human beings, it may be many decades before these results are 
confirmed. 
Melatonin also has benefits treating diseases. Cancer has been one of the deadliest 
diseases in human history. Many resources have been allotted to research treatment of 
cancer. As cancer is not a foreign invader of the body, it is difficult to prevent or treat. 
Cancer may be a natural consequence of age. The risk of cancer increases proportionally 
with age. With lower plasma melatonin levels and a weaker immune system, cancer may 
find less resistance to its establishment and growth in the body. Melatonin supplements 
and a strong immune system may lower the incidence of cancer in older people, but cancer 
will still occur. Melatonin may also help boost the effectiveness of current cancer 
treatments. 
Cancer acts on the biosynthetic production of melatonin. This was deduced at the 
University Women's Hospital in Tubingen Germany by eliminating the following 
possibilities First, malignant tumors did not accelerate the hydroxylation of melatonin in 
the liver. Detection ofmelatonin's primary metabolite (6-sulfatoxymelatonin) in urine 
samples of patients with malignant tumors was found in relative concentrations to 
melatonin as seen in patients with benign tumors (13). The maintenance of circadian 
profiles also rules out the possibility of a competitive interaction by an introduced enzyme. 
This knowledge is useful in detecting current pineal activity in cancer patients (13) 
Second, N-acetylserotonin levels are much higher in cancer patients than 
age-matched controls, while serotonin levels remained similar. This increase is not a result 
of reconversion from melatonin, as the levels ofN-acetylserotonin are close to one 
hundred fold higher than the levels of melatonin (13). This leads to the conclusion that 
N-acetylserotonin levels are prevented from being converted into melatonin by tumors. 
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Hydroxyindole-o-methyl transferase converts N-acetylserotonin into melatonin. Malignant 
tumors may produce responses in the immune system that interfere with the activity or 
availability of hydroxyindole-o-methyl transferase. More research is needed in this area. 
Melatonin inhibits the growth of hormone dependent human breast tumor cells, for 
example estrogen- responsive MCF-7 cell line. Melatonin's suppression ofMCF-7 growth 
is a combination of stimulating growth- inhibitory factors and down- regulating the 
expression of estrogen receptors (78). 
Estrogen and progesterone receptors are found on MCF-7 cells. MCF-7 cells are 
estrogen dependent, requiring estrogen for regulating their growth via RNA transcription 
and protein expression (33). Estrogen is autoregulatory, altering the concentrations of 
estrogen receptors in MCF-7 cells for optimal growth rates. Melatonin's influence over 
MCF-7 growth is not with regard to estrogen, but the estrogen- response pathway. Only 
human breast cancer cell lines with estrogen receptors are susceptible to the antirnitogenic 
effects of melatonin (50). Estrogen receptor protein production and estrogen binding 
affinity to estrogen receptors are decreased when physiological concentrations of night 
time melatonin are present. The rate of transcription of the estrogen receptor gene is 
decreased as a response to melatonin. Without estrogen receptors, MCF-7 cells could not 
regulate the key growth- regulatory factors, transforming growth factor alpha and beta 
(TGF alpha and TGFB) (78). Melatonin reduces the estrogen receptor concentration, 
stopping MCF-7 cell proliferation without regulation of growth factors or oncogene 
expression. 
Transforming growth factor- B, an inhibitory growth factor, production is 
decreased by estrogen ( 60). Melatonin decreases the production of estrogen receptors and 
reduces estrogen's affinity for its receptors. This action indirectly results in a TGFB 
increase and an inhibition ofMCF-7 cell proliferation. This supported melatonin's 
inhibition ofMCF-7 cell growth via the estrogen- response pathway. Melatonin's increase 
in TGFB expression is similar to the mechanism oftarnoxifen in inhibiting estrogen 
receptor positive breast cancer cell proliferation (60). 
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The early proto- oncogene c-jos transcripts are increased in number as a result of 
estrogen. C-jos increases MCF-7 proliferation and differentation. Molis found melatonin 
to initially increase c-jos. After this intial increase, melatonin significantly inhibits c-jos 
production by almost 80% (78) This reduction in c-jos would result in a reduced 
occurance of normal cells differentiating into malignant cells. 
PgR and pancreatic spasmolytic polypeptide (pS2) are MCF-7 intracellular 
proteins and easily referenced markers of estrogen receptor activation (78). PgR and pS2 
gene expression are enhanced by estrogen at the mRNA level. Melatonin inhibits the 
mRNA expression of PgR and estrogen receptors. Although the estrogen- response 
pathway regulates PgR production, melatonin does not inhibit PgR production via the 
estrogen- response pathway, as mRNA levels for PgR and estrogen receptor proteins 
decrease simultaneously. Melatonin inhibits production of estrogen receptor proteins and 
PgR individually at the transcriptional level. 
Melatonin's influence over the transcription ofpS2 is also independent of the 
inhibition of estrogen receptor protein transcripion, as melatonin stimulates pS2 
transcription. This difference in melatonin's regulation ofMCF-7 intracellular, estrogen 
stimulated proteins suggests multiple mechanisms for inhibition of estrogen dependent cell 
proliferation, in addition to a reduction in estrogen receptor concetration (78). 
The proto- oncogene c-myc, contributing to cellular proliferation and 
diferentiation, is stimulated by both estrogen and melatonin (78). Melatonin may regulate 
c-myc and c-jos with different mechanisms. Increased c-myc mRNA production, in 
response to melatonin, seemingly contradicts melatonin's inhibition ofMCF-7 
proliferation. Although, c-myc is a complex proto- oncogene, associated with tumor cell 
apoptosis at high concentrations (8). As c-jos and c-myc production are both stimulated 
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by estrogen, inhibition of both proto- oncogenes would be expected if melatonin reduced 
estrogen receptor concentrations. C-myc and c-jos mRNA expression both initially 
increase when exposed to melatonin. C-myc concentrations remain elevated, and c-jos 
concentrations steadily decrease after the initial elevation. Not only are different 
regulatory mechanisms suspected, the mechanisms may be initiated in time dependent 
stages (78). 
Melatonin's inhibition of PgR and c-jos production and increase in c-myc, pS2 and 
TGF B production may be a signal transduction effect resulting in an early stage inhibition 
of estrogen dependent cancer cell proliferation (78). The signal transduction may be 
triggered by a cell surface melatonin receptor. After six hours, melatonin begins to reduce 
the estrogen receptor concetrations, resulting in a late stage inhibition of cancer cell 
proliferation (78). A reduction in estrogen receptors also increases TGFB production, 
further reducing cancer cell proliferation and complimenting tamoxifen treatment. 
Melatonin has recently been shown to increase the anti tumor activity of interleukin 
2 (IL-2)(125). IL-2, produced by activated T cells, orchestrates the immune response 
against solid tumors. IL-2 does not suppress the growth of all types of solid tumors. Lung 
cancer and hepatocarcinoma do not regress with IL-2 activity alone. High levels of 
melatonin supplements increase the efficiency ofIL-2 and produce regression in these 
resistant forms of cancer (32). Melatonin may produce this amplification ofIL-2 antitumor 
activity by increasing the sensitivity of cancer cells to cytolysis induced by IL-2 
lymphocytes (125). Another possible mode of action is an increase in immune lymphocyte 
and eosinophil numbers (125). This is achieved through melatonin's stimulation of type 2 
T-helper cells, producing increases in IL4 and IL5. Melatonin also appears to increase 
macrophage-mediated suppression without diminishing the tumor necrosis factor (TNF) 
production (125). Macrophages and fibroblasts are stimulated by melatonin to increase 
colony stimulating activity. 
Another possibility for the increase in autoimmune disease in the elderly is a 
change in protein production with age (92). The proteins produced function similarly to 
proteins of youth, but they may have slightly different structures promoting an immune 
response. This possibility is related to DNA damage increasing with age, rather than 
immune system regression. It is unlikely to be the exclusive reason for an increase in 
autoimmune disease with age, but it is a contributing factor. 
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Melatonin's ability to alleviate immunodepression caused by acute stress, 
glucocorticoids or cancer is achieved through T -helper lymphocytes, not opioid peptides 
( 68). Immunodepression is often a cause of the progression of cancer. Melatonin 
stimulates T-helper cells to produce cytokines, which are integral with melatonin in 
retaining the delicate balance of the immune system. Melatonin stimulates the release of 
interleukin-2 andy-interferon (93). In addition to stimulating cytokine release, melatonin 
induces mRNA production for interleukin-I in human monocytes (79). A high-affinity 
binding site in bone marrow cells, specifically T -helper cells, was found to have a Kd of 
346 pM (67). Currently, hematopoietic cytokines and bone marrow transplants are used to 
alleviate the hematopoietic toxicity of chemotherapy that hampers drug dose levels and the 
inhibition of cancer growth. Recently, melatonin has been shown to provide the same 
results with fewer side effects, if any, at a reduced financial cost (67). 
These results were shown on mice infected with Lewis lung carcinoma and treated 
with etoposide. Melatonin protected the leukocytes, platelets and marrow 
granulocyte/macrophage-colony forming units (GM-CFU) from apoptosis caused by 
etoposide without a decrease in their anticancer action (67). Melatonin protected the 
GM-CFUs by inducing additional production of colony-stimulating factors (CSFs) (67). 
Anti-GM-CSF monoclonal antibodies prevented melatonin from protecting bone marrow 
cells from etoposide induced apoptosis. Melatonin was more effective at protecting the 
bone marrow, administered with chemotherapy, than accelerating the recovery of these 
bone marrow cells when given after the chemotherapy. This important use of melatonin 
should be considered and implemented by clinicians. 
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This protection was solidified when the number of lineage-committed myeloid 
precursor GMU-CFUs were observed to increase without the increase ofpluripotent 
spleen-colony forming units (S-CFU), with the addition of melatonin. An experiment using 
athyrnic nude mice led to the conclusion that melatonin can induce the production of 
endogenous CSFs, specifically GM-CSF, in T-lymphocytes and not macrophages (67). 
S-CFU was decreased in number when exposed to melatonin. This is caused by 
melatonin' s stimulation of IL4 production from type 2 T -helper cells and IL4' s inhibition 
ofS-CFU (12). 
GM-CFU numbers are increased with the addition of melatonin, beginning at 
melatonin's physiological concentration ofO. l nM. GM-CFU is produced by both T cells 
and stromal cells (37). When stromal cells were separated from T cells by adherence, 
melatonin had no affect on GM-CFU production in either T cells or stromal cells. This led 
to the conclusion that melatonin must stimulate the release ofIL4 from type 2 helper cells, 
which then acts on adherent stromal cells to produce GM-CSF. The addition of anti-IL4 
monoclonal antibodies negates the increase in GM-CFU numbers seen with exposure to 
melatonin. Although, melatonin will not increase GM-CFUs without GM-CSF, even with 
its stimulation of IL4 production. An additional, yet unknown, signal is needed which may 
be found in current chemotherapy drugs (121 ). These drugs are speculated to activate 
macrophages, possibly producing the needed signal molecule. 
Melatonin's regulation of the immune system equilibrium is critical for targeted 
responses to foreign microorganisms immunopathological disorders, autoimmune diseases, 
and reproduction (67). Melatonin's infuence on the reproductive and immune systems is 
based on its feedback loops created with type 1 and type 2 T -helper cells. Type 1 T-helper 
cells (Th 1) produce two cytokines related to melatonin stimulation, IL2 and yIFN. Type 2 
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T-helper cells (Th2) produce two different cytokines related to melatonin stimulation, IL4 
and ILS (28). The Th2 cells posess the high affinity melatonin receptor, and are 
melatonin's target T-helper cell. At physiological concentrations, melatonin stimulates Th2 
cells to produce IL4, which in tum stimulates granulocytes and macrophages to produce 
colony stimulating factors. y-IFN, produced by Thl cells, inhibits the production of 
cytokines form Th2 cells and stimulates melatonin production in the pineal gland (28). IL4 
inhibits yIFN production in Th I cells ( 12). Therefore, if IL4 is needed to stimulate 
GM-CSF, it will also inhibity-IFN production and melatonin production [Fig. 4]. This 
negative feedback prevents excessive IL4 concentrations. Accordingly, if melatonin levels 
are low, IL4 will no longer be available to inhibity-IFN production. The subsequent rise in 
yIFN production will increase melatonin production until IL4 levels inhibit yIFN 
production. This basic regulation of melatonin is complicated by the production of 
melatonin outside the pineal gland and the environmental influence of melatonin 
production. These factors alter the melatonin plasma concentrations and have an affect on 
the immune system through the Th2 cells. 
Melatonin's stimulation ofIL4 production has also been linked to successful 
pregnancy (67). IL4 has the ability to regulate cell cycle progression, inhibit the growth of 
human melanomas, enhance the antigenicity of melanoma cells and induce programmed 
cell death (70). Appropriate IL4 production is essential for cancer prevention. 
STRESS AND DISEASE 
The hippocampus inhibits the hypothalamic-pituitary-adrenal (HP A) axis. The 
hippocampus degenerates with age and with neurological impairment. This hippocampal 
degeneration is hypothesized to be the cause of increased cortisol secretion with age (35). 
This occurs through a reduction in the sensitivity of steroid feedback. Hippocampal 
degeneration and age increase and prolong the adrenocortical responses to stress. With 
chronic duration, adrenocortical responses to stress are a detriment to the body. A slowed 
reduction of stress related hormones increases the potential for cardiovascular disease, 
cancer, diabetes, hypertension and weakens the immune system( l 14). 
ACTH concentrations increase with age, compounding the problem of prolonged 
and increased response to stress. Lack of melatonin, with its ability to inhibit 
adrenocorticoid secretion, is the reason for elevated ACTH and cortisol plasma 
co11centrations (35). Adrenocorticoid secretion is primarily elevated at night, adding 
support to melatonin's inhibitory role. 
Each individual ages at a different rate. One leading theory to explain this is 
referred to as the rate of senescence. This theory claims the rate at which an individual 
ages is influenced by the cumulative exposure to stress and glucocorticoids (17). 
Glucocorticoids are responsible for hippocampal neuronal degeneration. The hippocampus 
is responsible for the inhibition of glucocorticoid release. As the hippocampus 
degenerates, not only is it exposed to higher and more sustained levels of glucocorticoids, 
its loss of neurons could be responsible for the memory loss seen with senescence (75)  
The HPA axis contributes to the normal homeostatic regulation of the body. This 
axis helps coordiMle neuroendocrine and metabolic responses to external and internal 
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stimuli. Excitement of the HPA axis allows the body to successfully react to short-term 
stress. The glucocorticoids secreted in response to short-term stress contribute to 
increased available glucose and lipids for energy and increased blood pressure and 
suppression of the immune system (114)  Chronic exposure to these conditions leads to 
higher associations with many age-related pathologies. This may be the result of a 
cumulative exposure to glucocorticoids. As the HP A axis becomes less sensitive to the 
negative feedback signals required to lower glucocorticoed levels, the prolonged exposure 
of glucocorticoids may further damage the HP A axis and its negative feedback 
mechanisms (114). 
The HP A axis begins with a signal from the suprahypothalamic brain, resulting 
from a stress. Hypophysiotropic peptides are released from the hypothalamus, regulating 
pituitary hormone secretion. These tropic hormones regulate adrenal hormone secretion. 
These adrenal hormones inhibit the HP A axis to form the negative feedback loop. The 
hippocampus has one of the highest concentrations of corticosteroid receptors in the brain 
(114). Thus, the hippocampus may be an important target offeedback inhibition. 
Decreases in corticosteroid receptors in the hippocampus with age leads to the prolonged 
recovery from an activated HP A resilience to stressors and increased secretion of ACTH 
and glucocorticoids (34). When the hippocampus is chronically exposed to high 
concentrations of glucocorticoids, the glucose transport in hippocampal neurons is 
disrupted (55). HPA hyperactivity, reduced resilience and high cumulative exposure to 
glucocorticoids increase the occurance of many age-related diseases, such as 
atherosclerosis, diabetes and cancer (114). HPA hyperactivity may also lead to impaired 
immune and cognitive function (54). Research is needed to determine ifa correlation 
between high cumulative glucocorticoid exposure and incidence of Alzheimer disease 
exists. 
High concentrations of cortisol and ACTH are seen in patients suffering from 
Alzheimer disease. The body is unable to reduce potentially damaging hormone levels as 
quickly as in youth. The SCN stimulates an increase in early morning glucocorticoid 
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levels. An early morning increase in glucocorticoid concentrations is stimulated by the 
SCN. This hormone release may help us to wake, and it would likely be linked to circadian 
cycles by the SCN. Without melatonin for inhibition, recovery from these levels is 
extended. This chronic exposure to glucocorticoids ages the body and weakens the 
immune system. Many forms of dementia exhibit disrupted central neurotransmitter 
function. 
Clinical assessments of ageing are based on the endocrine (hormone 
concentrations) and nervous (sympathetic) systems' integrity. Individual ageing rates vary 
depending on genetic and environmental influences on systems and tissues. For example, 
endocrine secretory tissue will vary in mass and cellular composition between each 
individual, as will hormone secretion rate, distribution space, hormone degradation and 
excretion rate, sensitivity to feedback regulation, and rhythmic secretory cycles (132). 
Most forms of dementia in aged individuals result from errors in protein 
production. The toxic protein piece that may produce Alzheimer's disease is 
42-arnino-acid-B-amyloid peptide. These peptides build up in the extracellular space, 
eventually forming plaques. These amyloid plaques toxically effect neurons by disrupting 
calcium equilibriums, producing oxygen free radicals and facilitating the aggregation of 
rnicroglia and infammation (38). Although amyloid plaques are not related to the severity 
of the dementia, the amyloid plaques may be an initial step, producing a cascade of events, 
culminating in clusters of neurofibrillary tangles formed with abnormal proteins, eventually 
producing severe dementia (38). These tau proteins disrupt rnicrotubule function in 
neurons and are relative to the severity of dementia. Preventing amyloid plaque deposits 
may help treat Alzheimer's in its early stages. 
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Patients with acute intermittent porphyria (A.IP), an autosomal dominant disorder 
disrupting the heme biosynthetic pathway, have reduced levels of plasma melatonin during 
the day and at night(IOO). A.IP patients also show increased levels oftryptophan and 
serotonin production(IOI). Heme arginate treatment of the disease decreases both the 
serotonin and tryptophan levels characteristic of A.IP, but does not raise the melatonin 
levels. Thus, the heme arginate treatment is reducing the serotonin and tryptophan 
concentrations by some other means than allowing them to be converted into melatonin. 
These low levels of melatonin may be the cause of acute, recurrent A.IP attacks by 
desynchronizing patients circadian rhythms, thus increasing the effects of environmental 
risk factors, such as, upsetting the equilibrium of the sex hormones. 
The question concerning why would melatonin levels be lower if its precursors, 
tryptophan and serotonin, are higher, has yet to be explained. This explanation would help 
identify a more poignant treatment than those currently used. As A.IP attacks cause 
debilitating loss of function in the peripheral, autonomic or central nervous system, the use 
of melatonin supplements for the prevention of such attacks or alleviation of symptoms 
should be explored. It is hypothesized that A.IP patients over produce delta-aminobutyric 
acid( Ala) in the Ii ver( I O I ) . 
Ala is a heme precursor, also producing the same effects as its structural analogue, 
GABA, inhibitory, on melatonin production in the pineal gland. The low plasma levels of 
melatonin are not related to the high tryptophan levels. Rather, they are directly related to 
a high level of Ala(IOI). Ala poorly penetrates the blood brain barrier, but would readily 
effect pinealocytes as the vascularzation of the pineal gland exists outside the barrier( IO I). 
The decrease in melatonin is caused by an increase in Ala concentration, not by a lack of 
hemoproteins(IOI). Ala blocks NAT activity, preventing the production of melatonin and 
the pinealoctye stimulatory response to NE(l O I). 
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Ala causes the low levels of melatonin, suggesting that environmental risk factors, 
and their related symptoms, are increased by low levels of circulating melatonin and not 
the cause of these low levels. Until it is determined if Ala overproduction is the exclusive 
cause of AIP, melatonin supplements may decrease the frequency and severity of acute 
AIP attacks 
CONCLUSION 
The retina relays photoperiod information to the SCN. This information is used to 
increase melatonin production at night and during the winter months. Vasopressin cells 
increase in concentration during winter months, increasing melatonin production, storage 
and secretion. The hypothalamus infuences gonadal steroid secretion via the pituitary 
gland, also signalling the pineal gland. Gonadal steroids have receptors in the pineal gland 
(influencing melatonin secretion) and in the hypothalamic- pituitary axis (infuencing 
gonadotropin release). Gonadotropins have receptors in the pineal gland. Melatonin 
significantly influences gonadotropin secretion (and, indirectly, gonadal steroid release) via 
modifications in LHRH and GnRH release. This complex feedback loop centers melatonin 
in the endocrine hormonal homeostasis of the body. 
Melatonin's progonadal or antigonadal actions depend on photoperiod, age and 
species. These modifications allow melatonin to regulate reproduction in seasonally 
breeding mammals by integrating photoperiod into the reproductive physiology. 
Conducting studies to determine if melatonin, supplemented to maintain an in vivo 
concentration similar to youth, extends average age spans in humans is problematic. 
Humans have relatively long life spans and the studies tracking individuals for many years 
are filled with unaccountable variables. Drosophila experiments have shown decreased life 
spans when their 24 hour days, based on light and dark cycles, are either increased or 
decreased to 27 and 21 hours respectively (134). Therefore, melatonin supplements may 
increase the average age of humans, but more importantly, melatonin supplements increase 
the quality of life in aged individuals. 
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So why is melatonin not prescribed by geriatricians on a widespread basis? The 
answer may lie in the fact that this prescription would require an off-label use. Doctors are 
often reluctant to prescribe drugs in a manner not precisely approved by the FDA, even if 
the use is supported by studies in multiple medical journals. Furthermore, the media is apt 
to follow this conservative decision, resulting in a public that is not given additional 
options, including the knowledge to ask their doctors questions. Obviously, this lack of 
medical education of the public is changing rapidly. In the near future, maybe taking your 
daily melatonin dose will be a common occurrence for almost everyone older than 
forty-five. 
From a geneticists viewpoint, every system in an organism is created to maximize 
reproductive viability at precisely the same time. Animals with a shorter life span become 
reproductively active at a comparatively faster rate. Organisms' reproductive systems 
reach maturity based on their endocrine system's time table. Gonadotropic hormones are 
regulated by the hypothalamus. The SCN, the internal clock of the body, is directly linked 
to the retina. Day and night cycles make an organism's biology aware of time. These 
circadian rhythms direct an organism's reproduction through the tropic hormone 
melatonin. 
Melatonin influences the ageing process indirectly through the reproductive 
system. When an organism has aged past prime reproductive viability, melatonin levels 
have already begun a gradual decline continuing until death. Most organisms live long 
enough to have multiple offspring or protect and raise the few offspring they have. Both 
strategies increase the potential for continuation of their DNA, and both require melatonin 
for survival. Animals do not have predestined times of death. Rather, the chance of death 
increases proportionally with age and inversely with melatonin production. 
The current theory of death through old age is the cumulative damage free radicals 
exert on the body and DNA Animals consume anti-oxidants from the environment to 
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prevent this damage. They also produce an anti-oxidant, melatonin. Organisms succumb to 
disease, cancer, viral and bacterial infections. Melatonin maintains a healthy, vibrant 
immune system. Melatonin links the immune system with the reproductive system. It 
protects an organism from death until it can produce offspring. The pineal gland and SCN 
are the biological clocks of the body. Melatonin is their administrator. Each is scheduled 
around the only time table important to any organism in an evolutionary sense, the 
reproductive system. Supplementing melatonin could increase the mean age of a 
population. It will increase the quality of life of the aged. It will prevent many diseases. It 
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